ESG

At Kyntra Bio, we have embraced a corporate vision statement across our enterprise: Our purpose is to develop novel therapies at the frontiers of cancer biology and rare disease.

Our vision is to advance the development of our innovative pipeline, with the aim of making a meaningful impact on the lives of patients in urgent need of transformative therapies.

To achieve this, our mission is to apply pioneering scientific and development expertise to deliver breakthrough therapies to patients.

To support this vision, we established a set of company-wide core values: Excellence, Empowerment, Integrity, and Respect for People.

Policy Links

Enterprise-Level Environmental Policy Human Rights Policy Code of Vendor and Partner Conduct Global Code of Ethics for Clinical Trials Corporate Governance

Excellence

At the core of our values is a commitment to excellence in all that we do.

Empowerment

  • We lead, inspire, trust, and encourage each other to share ideas and embrace new challenges.
  • We hold ourselves accountable to one another and to our commitment to patients.

Integrity

  • We uphold the highest ethical standards in our work to bring therapies to market, the science we perform, and our commitment to each other.
  • We expect honesty, fairness, and transparency in all of our interactions.

Respect for People

  • We foster individual growth and promote an environment that supports continuous learning.
  • We stand together as a community to build and sustain a culture of inclusiveness and equality.
  • We believe it is critical to conserve our world’s resources and strive to create a safe and healthy environment for our employees and patients.
  • We commit to treating each other with high regard and dignity.

These values are integral to our culture, rewards and recognition programs, and performance management systems.

Environment, Health, and Safety

For pharmaceutical companies, the product life cycle and supply chain require the use of valuable resources. Kyntra Bio is committed to continuously reducing its environmental footprint.

We have implemented several sustainability initiatives, including programs to recycle or donate electronic equipment, and have worked with collaborators to minimize the product packaging and adopt responsible shipping practices associated with our clinical and commercial activities.

See our Enterprise-Level Environmental Policy

Social Diversity, Equity, and Inclusion

The labor market in the biotechnology industry is extremely competitive and recruiting and retaining top talent is critical to the continued success of our business. We are highly committed to building and retaining a diverse, dedicated, and highly engaged team to deliver innovative therapies to patients facing serious unmet medical needs. Our core values of excellence, empowerment, integrity, and respect for people are fundamental to how we attract, grow, engage, and retain our people. We focus on recruiting, retaining, and developing employees from a diverse range of backgrounds to conduct our clinical development and administrative activities.

Our offerings include competitive, innovative, and equitable pay practices; comprehensive health and wellness benefits; retirement and life insurance offerings; development programs; and flexible work arrangements. We also sponsor an annual promotions nomination and approval process.

On our Board of Directors, 1 of 5 members (20%) are female and 1 of 5 members (20%) identify as Asian. As of October 2025, our US workforce is 49% female. Our US employees that self-report ethnicity are 54% Asian, Hispanic, or Black. Our average employee tenure is 7 years.

See our Human Rights Policy

Governance and Risk Management

To strengthen our corporate governance, we have made substantial improvements to our Sarbanes-Oxley compliance program and have enhanced our internal controls over financial reporting. Throughout the year, the Board and its committees engage with management to discuss a wide range of enterprise risks – including those related to Kyntra Bio’s operations, cybersecurity, and enterprise risk management (ERM) – and ensure alignment between risk mitigation strategies and business objectives.

We implemented an ERM program in 2022. Since then, we have performed enterprise risk assessments to help identify and manage risks and uncover opportunities that support the accomplishment of corporate goals. ERM informs all areas of our business, including how we approach emerging challenges and opportunities and allocate resources accordingly. One of the organic benefits of a formal ERM process is its ability to foster a risk-aware culture across all levels of the organization (enterprise, functional, and project specific) with a patient-first mindset. As we pursue our mission of delivering therapies in areas of significant unmet need, ERM facilitates and supports the delivery of our corporate objectives by helping us understand and evaluate risks and opportunities, and by establishing appropriate plans to manage them.

Regarding cybersecurity, our Board of Directors recognizes that it is a critical component of our overall risk management strategy. Throughout the year, the Board and its committees engage with management to monitor and mitigate a broad spectrum of risks, including cybersecurity. Our cross-functional approach includes oversight from our Cybersecurity Committee and is focused on preserving the confidentiality, security, and availability of company data by identifying, preventing, and responding to cybersecurity threats and incidents.

We continually invest in information and cybersecurity services and technologies. Technical safeguards are designed to protect our information systems, including firewalls, continuous intrusion detection and response systems, data leak prevention strategies, enhanced email protection software, anti-malware functionality, an email security platform, and identity access management (IAM) solutions with multi-factor authentication (MFA). These safeguards are regularly evaluated and improved through periodic assessments and review of cybersecurity threat intelligence. We also rely on third-party providers to support key elements of our cybersecurity program, such as Security Operations Center (SOC) monitoring, cloud and endpoint protection, and vulnerability management.

We provide regular cybersecurity training (at minimum annually) to equip our personnel with effective tools to recognize threats and respond appropriately. These trainings also communicate updates to the company’s information security policies and procedures.

Our compliance program is a core expression of our commitment to the value of integrity. Each year, all employees complete the annual compliance program, which emphasizes the shared responsibility for all colleagues to be good stewards of our organization through our commitment to maintaining the highest standards of business conduct and ethics. The program helps to ensure employees understand and agree to follow Kyntra Bio’s corporate policies, including the Anti-Bribery Policy, Code of Business Conduct and Ethics, Insider Trading and Trading Window Policy, Speak-Up and Reporting Policy, Social Media Policy, Related Persons Transactions, and SEC Compliance Policy.

See our Code of Vendor and Partner Conduct

See our Global Code of Ethics for Clinical Trials

Enterprise Level Environmental Policy

For pharmaceutical companies, general operations, the product life cycle, and the supply chain require the use of valuable water, energy, and other resources. Kyntra Bio is committed to complying with all applicable environmental rules and regulations, and to reducing our environmental footprint. We strive to protect our employees, facilities, and the community from harmful environmental influences and, at the same time, promote environmental awareness and sustainability.

Human Rights Policy

Kyntra Bio is committed to respecting human dignity and upholding human rights in all aspects of our work. We believe that human rights are fundamental freedoms to which all people are entitled, regardless of race, sex, nationality, ethnicity, religion, or any other status. We practice this belief every day through our mission to improve the lives of patients globally.  We encourage and expect all employees, contractors, and business associates to practice and promote human rights at all times, as exemplified in the United Nations Universal Declaration of Human Rights and the International Bill of Human Rights.

Code of Vendor and Partner Conduct Policy

To support our vision of improving the lives of people globally, Kyntra Bio partners with third-party individuals and organizations that share our values and commitment to ethical, compliant, and socially responsible practices. We expect our vendors and partners to conduct business with integrity throughout the business engagement and continuously improve their efforts and performance over time. At a minimum, they must adopt and adhere to their own code of business ethics and conduct, which should include clear principles and standards related to labor and human rights, equal opportunity and nondiscrimination, workforce diversity and pay equity, health and safety, environmental sustainability, anti-bribery, data privacy and information protection, trade sanctions and export control, quality, and management systems.

Kyntra Bio Global Code of Ethics for Clinical Trials

Kyntra Bio’s mission is to improve the lives of people globally by developing innovative therapies anchored in high-quality science and our passion for patients. We treat patient safety as a top priority and hold ourselves accountable to the highest ethical principles and standards in our clinical trials, whether independently or in collaboration with partners, contract research organizations, or other third parties. All Kyntra Bio-sponsored clinical trials are conducted in accordance with the applicable regulations, Health Authority standards, and Good Clinical Practice (GCP) guidelines. Kyntra Bio maintains internal procedures to ensure compliance with the applicable clinical trial standards as it pertains to:

Appropriateness

All research should be designed to address a legitimate scientific question or need.

Selection of Investigators

Kyntra Bio selects clinical investigators who possess the necessary qualifications, training, research, and clinical expertise, as well as the potential to recruit research participants. The independence of clinical investigators and others involved in clinical research is critical to protect the best interest of research participants. Kyntra Bio does not engage any clinical investigators who have been debarred, disqualified, or restricted from participating in clinical research.

Ethical Review

Kyntra Bio-sponsored trials undergo an ethical review by a qualified independent committee (Institutional Review Board/Independent Ethics Committee) prior to study initiation.

Privacy

Kyntra Bio is committed to protecting patients’ privacy, collecting minimal subject identifiers, and complying with all applicable privacy laws and regulations.

Integrity of Clinical Data

Kyntra Bio ensures data are reliable, processed accurately, and reported in accordance with established data integrity standards.

Informed Consent

Kyntra Bio requires voluntary informed consent from all research participants. Consent materials outline known benefits and risks of the trial, and additional safeguards are implemented to protect minors.

Safety Monitoring

Kyntra Bio monitors patient safety throughout the duration of clinical trials, including long-term follow-up when appropriate. Adverse event information is collected, processed, reported, analyzed, and communicated in a timely manner. Clinical investigators are expected to report adverse events and provide timely updates to participants and others, as appropriate.

Compensation

We ensure that any payments, injury compensation, and other benefits provided to research participants are appropriate and do not unduly influence their decision to participate in a clinical research study. Investigator payments are based on services rendered and must align with Fair Market Value (FMV) and Kyntra Bio’s HCP/FMV policy, as well as local regulations.

Investigator Meetings

Kyntra Bio ensures that investigator meetings are modest in location and cost for the purpose of training study staff on participating in a Kyntra Bio clinical trial. Investigators are not paid for their time, but Kyntra Bio provides reasonable accommodations in compliance with Kyntra Bio’s HCP/FMV policy and local country requirements.

Transparency

Kyntra Bio publicly discloses information about its clinical trials in compliance with the applicable regulations, Health Authority standards, and GCP guidelines. We are also committed to publishing clinical trial results, regardless of outcome or regulatory approval.

Diversity

Kyntra Bio strives to conduct clinical trials without bias. We are committed to identifying and reducing the potential barriers to clinical trial access and participation. We strive to improve subject recruitment, enrollment, and retention processes to ensure disease-appropriate subject representation and greater inclusion of patients across racial, ethnic, gender, age, and socioeconomic groups.